These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30629858)

  • 21. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    Ahmed AM; Doheim MF; Mattar OM; Sherif NA; Truong DH; Hoa PTL; Hirayama K; Huy NT
    J Med Virol; 2018 May; 90(5):907-918. PubMed ID: 28892235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
    Eley T; Garimella T; Li W; Bertz RJ
    Clin Pharmacokinet; 2015 Dec; 54(12):1205-22. PubMed ID: 26177803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
    Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
    J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
    [No Abstract]   [Full Text] [Related]  

  • 25. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
    Zeuli JD; Adie SK; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
    Kan H; Hiraga N; Imamura M; Hayes CN; Uchida T; Miyaki E; Tsuge M; Abe H; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antivir Ther; 2016; 21(4):307-15. PubMed ID: 26562322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
    Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
    Ward T; Webster S; Mishina S; McEwan P; Wygant G; Wang F
    Value Health Reg Issues; 2017 May; 12():1-6. PubMed ID: 28648305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
    Nakamura Y; Imamura M; Kawakami Y; Teraoka Y; Daijo K; Honda F; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Chayama K
    J Med Virol; 2017 Apr; 89(4):665-671. PubMed ID: 27602542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.
    Murray M
    Curr Drug Metab; 2024 Mar; ():. PubMed ID: 38441017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
    Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.
    Friborg J; Zhou N; Han Z; Yang X; Falk P; Mendez P; McPhee F
    Infect Dis Ther; 2014 Dec; 4(1):137-44. PubMed ID: 25516102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
    Shiozaki T; Ueno T; Nagashima H; Yamahira N; Hiraoka M; Eley T; Bifano M; Bertz RJ
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):292-302. PubMed ID: 25740262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.
    Wang HC; Ren YP; Qiu Y; Zheng J; Li GL; Hu CP; Zhou TY; Lu W; Li L
    Acta Pharmacol Sin; 2018 Jan; 39(1):140-153. PubMed ID: 28880015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution.
    Eley T; Garimella T; Li W; Bertz RJ
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):195-200. PubMed ID: 28263460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.